Coles shares: Broker says the 'risk-reward is attractive'

Ord Minnett has good things to say about the supermarket giant following its quarterly update.

| More on:
Happy couple laughing while shopping in supermarket

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coles Group Ltd (ASX: COL) shares have been having a volatile year with plenty of ups and downs.

But according to one leading broker, it could be onwards and upwards from here.

What is the broker saying about Coles shares?

According to a note out of Ord Minnett, its analysts believe that the supermarket and liquor giant could be a top option for investors following its recent quarterly update.

The broker highlights that Coles delivered a solid update, which demonstrated strong execution and clear cost discipline. It feels that this bodes well for the future. Its analysts said:

Coles provided a solid update for the September quarter. The company demonstrated strong execution with healthy first-quarter FY25 sales and clear cost discipline. Secondly, tightly managed capital expenditure (capex) should reward shareholders with healthy free cash flow (FCF) and dividends.

Ord Minnett is also feeling positive about the future due to several earnings drivers. But despite this positive outlook, it notes that its shares trade at a sizeable discount to rival Woolworths Group Ltd (ASX: WOW). It adds:‍

Beyond FY25, Coles has several earnings drivers in FY26, underpinning our confidence in earnings growth. The risk-reward is attractive, with Coles now trading at a 16% discount to arch-rival Woolworths (WOW).

And while there are a number of risks to be wary of, such as regulatory scrutiny and negative media coverage, the broker highlights that it has been business as usual inside its supermarkets. It explains:‍

Coles is navigating a challenging period for Australian supermarkets, managing government and regulatory scrutiny, deflation, and cost pressures effectively. The group's strategy to focus on its core food business while maintaining cost control is proving successful. Coles has not seen significant changes in consumer behaviour around promotions or promotional funding, and its promotional strategy is improving consumer value perceptions.

Shares upgraded

‍Overall, Ord Minnett remains very positive on the company's future and thinks it would be a good option for investors right now. This saw it recently upgrade Coles shares from a hold rating to an accumulate rating with an improved price target of $19.50.

Based on its current share price of $18.16, this implies potential upside of 7.4% for investors over the next 12 months. And including dividends, the total return stretches beyond 11%. The broker concludes:

Coles should have considerable savings to invest for growth in FY26, supporting profit delivery and market share gains. We have lowered our food gross margin forecasts for FY25 and raised our depreciation and amortisation estimates, which has resulted in an approximately 5% reduction in our full-year EPS forecast. We have moved our recommendation to Accumulate from Hold and our price target has increased to $19.50 from $19.00.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Coles Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

Beef cattle in stockyard.
Consumer Staples & Discretionary Shares

Queensland floods to have a 'material' impact on this ASX agricultural stock's earnings

This company is likely to experience a material hit to earnings as a result of the floods in Queensland.

Read more »

A wine technician in overalls holds a glass of red wine up to the light and studies it.
Consumer Staples & Discretionary Shares

Treasury Wine shares keep the good times flowing

Brokers warn that the current lift is likely to be fragile.

Read more »

A man pushes a supermarket trolley with phone in hand down a supermarket aisle looking at the products on the shelves.
Consumer Staples & Discretionary Shares

Are Coles or Woolworths shares a better buy in 2026?

Which supermarket giant is the better buy this year?

Read more »

Young fruit picker clipping bunch of grapes in vineyard.
Consumer Staples & Discretionary Shares

Down over 50%, is this the ASX 200's greatest recovery share for 2026?

After a brutal year, Treasury Wine shares have been deeply sold off. Is a recovery starting to take shape for…

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Consumer Staples & Discretionary Shares

This ASX All Ords stock edges lower as investors digest key milestone

After completing a major acquisition, this ASX All Ords stock is back in focus as investors assess the next phase.

Read more »

A little boy surrounded by green grass and trees looks up at the sky, waiting for rain or sunshine.
Consumer Staples & Discretionary Shares

Why is Cobram Estate rocketing 17% today?

Cobram Estate shares jump 17% today after a broker upgrade and renewed confidence in its US growth plans.

Read more »

A young farnmer raise his arms to the sky as he stands in a lush field of wheat or farmland.
Consumer Staples & Discretionary Shares

These agricultural stocks are fundamentally undervalued, Bell Potter says

Bell Potter has named three stocks in the agricultural sector that it believes to be fundamentally undervalued.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Consumer Staples & Discretionary Shares

Why this ASX small-cap share is back in focus after a US market update

A fresh US update has put Bubs shares back on investors’ radars as FDA approval moves closer and sales continue.

Read more »